Sign In
Buy GLUE
$16.52
-6.16 (-27.16%)
At Close: Jul 31, 2026
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, i
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Monday, 23'rd Feb 2026
BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ann
3 High-Risk Stocks That Soared in 2025 But Can Still Fly Higher
10:02am, Friday, 06'th Feb 2026
There is a growing sentiment that high-risk stocks—particularly some high-growth tech stocks—will be out of favor in 2026. It's helpful to look at a statement like this on two levels.
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of “Moderate Buy” by Brokerages
05:24am, Sunday, 11'th Jan 2026
Shares of Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eight brokerages that are currently covering the firm, Market
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
10:49pm, Thursday, 08'th Jan 2026
BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc . (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug
12:10pm, Thursday, 08'th Jan 2026
Monte Rosa shares surge 45% after interim phase I data show that MRT-8102 drives deep NEK7 degradation and reduces sharp inflammation markers.
Monte Rosa Therapeutics (GLUE) is on the Move, Here's Why the Trend Could be Sustainable
09:55am, Thursday, 08'th Jan 2026
Monte Rosa Therapeutics (GLUE) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Monte Rosa Therapeutics: Competitive MRT-8102 Results Offer Additional Platform Validation
08:00am, Thursday, 08'th Jan 2026
Monte Rosa Therapeutics delivered strong interim phase 1 results for MRT-8102, showing deep NEK7 degradation and competitive hsCRP reductions in cardiovascular risk patients. The results further valid
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
04:01pm, Wednesday, 07'th Jan 2026
BOSTON, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based m
Monte Rosa Therapeutics (GLUE) Upgraded to Strong Buy: Here's Why
01:01pm, Wednesday, 07'th Jan 2026
Monte Rosa Therapeutics (GLUE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term
Monte Rosa's Experimental Drug Slashes Inflammation Linked To Heart Disease
10:09am, Wednesday, 07'th Jan 2026
Monte Rosa revealed positive interim Phase 1 data of MRT-8102. Data showed safety, tolerability, and reduction in inflammatory markers.
In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonst
Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results
04:05pm, Tuesday, 06'th Jan 2026
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ann
Analyzing Monte Rosa Therapeutics (NASDAQ:GLUE) and NextCure (NASDAQ:NXTC)
02:14am, Sunday, 21'st Dec 2025
Monte Rosa Therapeutics (NASDAQ: GLUE - Get Free Report) and NextCure (NASDAQ: NXTC - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two co
Monte Rosa Scores A Win In Prostate Cancer, And Rockets To A Four-Year High
01:34pm, Tuesday, 16'th Dec 2025
Monte Rosa Therapeutics surged Tuesday after the biotech said every patients in a prostate cancer study responded to its treatment.
